Paris, France and Manchester, UK – 19 May 2026 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces
Novacyt S.A. (AIM:NCYT) Full year trading update
Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
Novacyt S.A. (AIM: NCYT) London Vet Show: Launch of animal multiplex assays
Launch of new animal multiplex assays at London Vet Show Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs
Novacyt S.A. (LON:NCYT) Settlement of the dispute with the DHSC
Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the
Novacyt S.A. (AIM:NCYT) Directorate Changes and FY 23 results update
Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces changes to the Board of Directors.
Novacyt S.A. (AIM:NCYT) Update on Taiwan laboratory disposal
Paris, France, Eastleigh and Manchester, UK – 21 December 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an update to the
Novacyt S.A. (AIM:NCYT) Completion of acquisition of Yourgene Health plc
The acquisition adds scale and diversification to create a stronger global diagnostics business, with a complementary suite of genomic technologies and services
Yourgene Health PLC (AIM:YGEN) Rule 2.7 Announcement
RECOMMENDED CASH OFFER by Novacyt UK Holdings Limited (a wholly-owned subsidiary of Novacyt S.A.) for Yourgene Health plc to be effected by means of a Scheme of Arrangement under Part
Novacyt S.A. Final Results, Full year revenue and EBITDA
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
What’s Green About This? The DRC is the world’s largest producer of cobalt
The production of electric vehicles depends on minerals that are increasingly unavailable for mining in the US, causing their production to be outsourced to places like the Democratic Republic of
Novacyt S.A. (AIM:NCYT) DHSC Claim update – Trial date listed
Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt
Novacyt S.A. (AIM:NCYT) Approval of genesig COVID-19 3G PCR test in UK
Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation